FCRL3

Across TCGA pan-cancer cohorts, FCRL3 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of FCRL3’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where FCRL3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FCRL3 is over-expressed in tumor, although a few such as COAD and THCA show the opposite, repressed pattern.

KIRC, COAD, and HNSC are the cancer types where FCRL3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FCRL3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+0.906	<.001	10	view →
COAD	Female	II,III,IV	−0.708	<.001	8	view →
HNSC	All	II,III,IV	+0.235	.006	6	view →
BRCA	All	All	+0.416	<.001	4	view →
STAD	Female	All	+1.160	.018	3	view →
THCA	All	All	−0.587	.012	2	view →
LUAD	All	All	+0.398	.010	2	view →
CHOL	All	II,III,IV	−0.370	.040	2	view →
ESCA	All	All	+0.801	.022	1	view →
LIHC	Male	All	−0.170	.044	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

FCRL3–KIRC

Open the KIRC breakdown →